€2.59 -0.0 -0.2%
Last Trade - 3:30pm
| Market Cap | £85.6m |
| Enterprise Value | £54.5m |
| Revenue | £2.93m |
| Position in Universe | 532nd / 847 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13.8 | 11.2 | 7.10 | 9.06 | 5.32 | 3.95 | 1.67 | 1.33 | -22.1% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | May 30, 2006 |
| Public Since | July 7, 2006 |
| No. of Shareholders: | n/a |
| No. of Employees: | 77 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Euronext - Brussels |
| Shares in Issue | 38,291,950 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Gaston Geenslaan 1, HEVERLEE, 3001, Belgium |
| Web | https://www.oxurion.com |
| Phone | +32 16 751310 |
| Contact | Wouter Piepers (Global Head of Corporate Communications and Investor Relations) |
| Auditors | BDO Reviseurs d Entreprises |
As of 3:30pm, shares in Oxurion NV are trading at €2.59, giving the company a market capitalisation of £85.6m. This share price information is delayed by 15 minutes.
Shares in Oxurion NV are currently trading at €2.59 and the price has moved by -13.79% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oxurion NV price has moved by -22.16% over the past year.
Of the analysts with advisory recommendations for Oxurion NV, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Oxurion NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Oxurion NV is scheduled to issue upcoming financial results on the following dates:
Oxurion NV does not currently pay a dividend.
Oxurion NV does not currently pay a dividend.
Oxurion NV does not currently pay a dividend.
To buy shares in Oxurion NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Oxurion NV are currently trading at €2.59, giving the company a market capitalisation of £85.6m.
Here are the trading details for Oxurion NV:
Based on an overall assessment of its quality, value and momentum, Oxurion NV is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Oxurion NV are currently priced at €2.59. At that level they are trading at 0.13% discount to the analyst consensus target price of 0.00.
Analysts covering Oxurion NV currently have a consensus Earnings Per Share (EPS) forecast of -0.8 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oxurion NV. Over the past six months, the relative strength of its shares against the market has been -11.98%. At the current price of €2.59, shares in Oxurion NV are trading at -4.2% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Oxurion NV.
Oxurion NV's management team is headed by:
Here are the top five shareholders of Oxurion NV based on the size of their shareholding:
